Skip to content

Study · Randomized controlled trial · 2026

11 results

Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.

Ruotolo G, Harris C, Lin Y, Wilson JM, Pirro V, Duffin KL, Thomas MK, Hartman ML, Neill CO, Coskun T, Milicevic Z, Haupt A, Sattar N, Nicholls SJ

Diabetes, obesity & metabolism17 Aug 2026Cited by 1 (Europe PMC)

PMID42608321 (opens in a new tab)PMCIDPMC13646367 (opens in a new tab)DOI10.1111/dom.71200 (opens in a new tab)PepBankPUB-42608321
Read at sourcePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, with or without type 2 diabetes, retatrutide lowered non-HDL cholesterol versus placebo in both phase 2 studies.

    In plain wordsIn adults with obesity or overweight, retatrutide lowered non-HDL cholesterol more than placebo, with or without type 2 diabetes.

    Peptide
    Retatrutide
    Outcome
    DecreaseNon-HDL cholesterol
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    0.5/4/8/12 mg (Study 1); 1/4/8/12 mg (Study 2) · 36 weeks (Study 1); 48 weeks (Study 2)As given in this study (human).

    Measurements

    Non-HDL cholesterol change, maximum
    −21%
    Study 1
    Non-HDL cholesterol change, maximum
    −26.9%
    Study 2

    Source sentences

    Summary
    significant reductions in non-high-density lipoprotein cholesterol (Study 1: up to -21.0%, Study 2: up to -26.9%
    1 context sentence
    Summary · context
    In Study 1, adults with obesity/overweight and T2D received once-weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical obesity without T2D received retatrutide (1/4/8/12 mg) or placebo for 48 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, with or without type 2 diabetes, retatrutide lowered apolipoprotein B versus placebo in both phase 2 studies.

    In plain wordsIn adults with obesity or overweight, retatrutide lowered apolipoprotein B more than placebo, with or without type 2 diabetes.

    Peptide
    Retatrutide
    Outcome
    DecreaseApolipoprotein B
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    0.5/4/8/12 mg (Study 1); 1/4/8/12 mg (Study 2) · 36 weeks (Study 1); 48 weeks (Study 2)As given in this study (human).

    Measurements

    Apolipoprotein B change
    −21.4%
    Study 1
    Apolipoprotein B change
    −24.2%
    Study 2

    Source sentences

    Summary
    apolipoprotein B (-21.4%, -24.2%
    1 context sentence
    Summary · context
    In Study 1, adults with obesity/overweight and T2D received once-weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical obesity without T2D received retatrutide (1/4/8/12 mg) or placebo for 48 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, with or without type 2 diabetes, retatrutide lowered total triglyceride-rich lipoprotein particles versus placebo in both studies.

    In plain wordsIn adults with obesity or overweight, retatrutide lowered triglyceride-rich lipoprotein particles more than placebo, with or without type 2 diabetes.

    Peptide
    Retatrutide
    Outcome
    DecreaseTotal triglyceride-rich lipoprotein particles
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    0.5/4/8/12 mg (Study 1); 1/4/8/12 mg (Study 2) · 36 weeks (Study 1); 48 weeks (Study 2)As given in this study (human).

    Measurements

    Total TRL particles change
    −22.5%
    Study 1
    Total TRL particles change
    −33.7%
    Study 2

    Source sentences

    Summary
    total triglyceride-rich lipoprotein particles (-22.5%, -33.7%
    1 context sentence
    Summary · context
    In Study 1, adults with obesity/overweight and T2D received once-weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical obesity without T2D received retatrutide (1/4/8/12 mg) or placebo for 48 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, with or without type 2 diabetes, retatrutide lowered large triglyceride-rich lipoprotein particles versus placebo in both studies.

    In plain wordsIn adults with obesity or overweight, retatrutide lowered large triglyceride-rich lipoprotein particles more than placebo, with or without type 2 diabetes.

    Peptide
    Retatrutide
    Outcome
    DecreaseLarge triglyceride-rich lipoprotein particles
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    0.5/4/8/12 mg (Study 1); 1/4/8/12 mg (Study 2) · 36 weeks (Study 1); 48 weeks (Study 2)As given in this study (human).

    Measurements

    Large TRL particles change
    −84.4%
    Study 1
    Large TRL particles change
    −76.6%
    Study 2

    Source sentences

    Summary
    large triglyceride-rich lipoprotein particles (-84.4%, -76.6%
    1 context sentence
    Summary · context
    In Study 1, adults with obesity/overweight and T2D received once-weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical obesity without T2D received retatrutide (1/4/8/12 mg) or placebo for 48 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, with or without type 2 diabetes, retatrutide lowered triglyceride-rich lipoprotein cholesterol versus placebo in both studies.

    In plain wordsIn adults with obesity or overweight, retatrutide lowered triglyceride-rich lipoprotein cholesterol more than placebo, with or without type 2 diabetes.

    Peptide
    Retatrutide
    Outcome
    DecreaseTriglyceride-rich lipoprotein cholesterol
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    0.5/4/8/12 mg (Study 1); 1/4/8/12 mg (Study 2) · 36 weeks (Study 1); 48 weeks (Study 2)As given in this study (human).

    Measurements

    TRL cholesterol change
    −29.4%
    Study 1
    TRL cholesterol change
    −38.6%
    Study 2

    Source sentences

    Summary
    triglyceride-rich lipoprotein cholesterol (-29.4%, -38.6%
    1 context sentence
    Summary · context
    In Study 1, adults with obesity/overweight and T2D received once-weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical obesity without T2D received retatrutide (1/4/8/12 mg) or placebo for 48 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, with or without type 2 diabetes, retatrutide lowered total LDL particles versus placebo in both studies.

    In plain wordsIn adults with obesity or overweight, retatrutide lowered total LDL particle numbers more than placebo, with or without type 2 diabetes.

    Peptide
    Retatrutide
    Outcome
    DecreaseTotal low-density lipoprotein particles
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    0.5/4/8/12 mg (Study 1); 1/4/8/12 mg (Study 2) · 36 weeks (Study 1); 48 weeks (Study 2)As given in this study (human).

    Measurements

    Total LDL particles change
    −19.7%
    Study 1
    Total LDL particles change
    −23.5%
    Study 2

    Source sentences

    Summary
    total low-density lipoprotein particles (-19.7%, -23.5%
    1 context sentence
    Summary · context
    In Study 1, adults with obesity/overweight and T2D received once-weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical obesity without T2D received retatrutide (1/4/8/12 mg) or placebo for 48 weeks.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight, with or without type 2 diabetes, retatrutide lowered small LDL particles versus placebo in both studies.

    In plain wordsIn adults with obesity or overweight, retatrutide lowered small LDL particle numbers more than placebo, with or without type 2 diabetes.

    Peptide
    Retatrutide
    Outcome
    DecreaseSmall low-density lipoprotein particles
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    0.5/4/8/12 mg (Study 1); 1/4/8/12 mg (Study 2) · 36 weeks (Study 1); 48 weeks (Study 2)As given in this study (human).

    Measurements

    Small LDL particles change
    −32.6%
    Study 1
    Small LDL particles change
    −32.3%
    Study 2

    Source sentences

    Summary
    small low-density lipoprotein particles (-32.6%, -32.3%
    1 context sentence
    Summary · context
    In Study 1, adults with obesity/overweight and T2D received once-weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical obesity without T2D received retatrutide (1/4/8/12 mg) or placebo for 48 weeks.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with obesity without type 2 diabetes, retatrutide lowered high-sensitivity C-reactive protein versus placebo.

    In plain wordsIn adults with obesity without type 2 diabetes, retatrutide lowered the inflammation marker CRP more than placebo.

    Peptide
    Retatrutide
    Outcome
    DecreaseHigh-sensitivity C-reactive protein, Study 2
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    0.5/4/8/12 mg (Study 1); 1/4/8/12 mg (Study 2) · 36 weeks (Study 1); 48 weeks (Study 2)As given in this study (human).

    Measurements

    hsCRP change
    −54.8%
    Study 2

    Source sentences

    Summary
    Retatrutide was associated with significant reductions in high-sensitivity C-reactive protein (-54.8%) and interleukin-6 (-29.6%) in Study 2 but not Study 1.
    1 context sentence
    Summary · context
    In Study 1, adults with obesity/overweight and T2D received once-weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical obesity without T2D received retatrutide (1/4/8/12 mg) or placebo for 48 weeks.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In adults with obesity without type 2 diabetes, retatrutide lowered interleukin-6 versus placebo.

    In plain wordsIn adults with obesity without type 2 diabetes, retatrutide lowered the inflammation marker interleukin-6 more than placebo.

    Peptide
    Retatrutide
    Outcome
    DecreaseInterleukin-6, Study 2
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    0.5/4/8/12 mg (Study 1); 1/4/8/12 mg (Study 2) · 36 weeks (Study 1); 48 weeks (Study 2)As given in this study (human).

    Measurements

    Interleukin-6 change
    −29.6%
    Study 2

    Source sentences

    Summary
    Retatrutide was associated with significant reductions in high-sensitivity C-reactive protein (-54.8%) and interleukin-6 (-29.6%) in Study 2 but not Study 1.
    1 context sentence
    Summary · context
    In Study 1, adults with obesity/overweight and T2D received once-weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical obesity without T2D received retatrutide (1/4/8/12 mg) or placebo for 48 weeks.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight and type 2 diabetes, retatrutide did not significantly change high-sensitivity C-reactive protein versus placebo.

    In plain wordsIn adults with obesity or overweight and type 2 diabetes, retatrutide did not change the inflammation marker CRP significantly compared with placebo.

    Peptide
    Retatrutide
    Outcome
    No significant changeHigh-sensitivity C-reactive protein, Study 1
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    0.5/4/8/12 mg (Study 1); 1/4/8/12 mg (Study 2) · 36 weeks (Study 1); 48 weeks (Study 2)As given in this study (human).

    Source sentences

    Summary
    Retatrutide was associated with significant reductions in high-sensitivity C-reactive protein (-54.8%) and interleukin-6 (-29.6%) in Study 2 but not Study 1.
    1 context sentence
    Summary · context
    In Study 1, adults with obesity/overweight and T2D received once-weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical obesity without T2D received retatrutide (1/4/8/12 mg) or placebo for 48 weeks.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight and type 2 diabetes, retatrutide did not significantly change interleukin-6 versus placebo.

    In plain wordsIn adults with obesity or overweight and type 2 diabetes, retatrutide did not change interleukin-6 significantly compared with placebo.

    Peptide
    Retatrutide
    Outcome
    No significant changeInterleukin-6, Study 1
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    0.5/4/8/12 mg (Study 1); 1/4/8/12 mg (Study 2) · 36 weeks (Study 1); 48 weeks (Study 2)As given in this study (human).

    Source sentences

    Summary
    Retatrutide was associated with significant reductions in high-sensitivity C-reactive protein (-54.8%) and interleukin-6 (-29.6%) in Study 2 but not Study 1.
    1 context sentence
    Summary · context
    In Study 1, adults with obesity/overweight and T2D received once-weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical obesity without T2D received retatrutide (1/4/8/12 mg) or placebo for 48 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT04881760

A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

Eli Lilly and Companyn = 33820 May 2021 to 22 Nov 2022

Obesity · Overweight

Trial pageClinicalTrials.govUpdated 13 Sept 2023
CompletedPhase 2Results postedNCT04867785

A Study of LY3437943 in Participants With Type 2 Diabetes

Eli Lilly and Companyn = 28113 May 2021 to 27 Oct 2022

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 3 Jul 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 8Current

    28 Oct 2026, 02:03 UTC

    The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    9 Oct 2026, 19:08 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.